PLoS ONE (Jan 2023)

HIV virologic response, patterns of drug resistance mutations and correlates among adolescents and young adults: A cross-sectional study in Tanzania.

  • Joan Rugemalila,
  • Doreen Kamori,
  • Peter Kunambi,
  • Mucho Mizinduko,
  • Amon Sabasaba,
  • Salim Masoud,
  • Frank Msafiri,
  • Sabina Mugusi,
  • Rita Mutagonda,
  • Linda Mlunde,
  • Davis Amani,
  • Erick Mboya,
  • Macdonald Mahiti,
  • George Ruhago,
  • Jeremiah Mushi,
  • Veryeh Sambu,
  • George Mgomella,
  • Boniface Jullu,
  • Werner Maokola,
  • Prosper Njau,
  • Beatrice Mutayoba,
  • Godfrey Barabona,
  • Takamasa Ueno,
  • Andrea Pembe,
  • Tumaini Nagu,
  • Bruno Sunguya,
  • Said Aboud

DOI
https://doi.org/10.1371/journal.pone.0281528
Journal volume & issue
Vol. 18, no. 2
p. e0281528

Abstract

Read online

BackgroundThe emergence of HIV drug resistance mutations (DRMs) is of significant threat to achieving viral suppression (VS) in the quest to achieve global elimination targets. We hereby report virologic outcomes and patterns of acquired DRMs and its associated factors among adolescents and young adults (AYA) from a broader HIV drug resistance surveillance conducted in Tanzania.MethodsData of AYA was extracted from a cross-sectional study conducted in 36 selected facilities using a two-stage cluster sampling design. Dried blood spot (DBS) samples were collected and samples with a viral load (VL) ≥1000 copies/mL underwent genotyping for the HIV-1 pol gene. Stanford HIV database algorithm predicted acquired DRMs, Fisher's exact test and multivariable logistic regression assessed factors associated with DRMs and VS, respectively.FindingsWe analyzed data of 578 AYA on antiretroviral therapy (ART) for 9-15 and ≥ 36 months; among them, 91.5% and 88.2% had VS (VLConclusionsVS amongst AYA is lower than the third UNAIDs target. Additionally, a high prevalence of ADR and high levels of circulating clinically relevant DRMs may compromise the long-term VS in AYA. Furthermore, the first VL result of ≥1000copies/ml after ART initiation is a significant risk factor for developing DRMs. Thus, strict VL monitoring for early identification of treatment failure and genotypic testing during any ART switch is recommended to improve treatment outcomes for AYA.